title: Follicle cyst formation after administration of different gonadotrophin-releasing hormone analogues for assisted reproduction.
abstract: The aim of this study was to examine the occurrence of ovarian cysts during the administration of three different gonadotrophin-releasing hormone analogues (GnRHa) in the long protocol as well as their characteristics, management and outcome compared with patients with no cyst formation. A total of 172 in-vitro fertilization (IVF) cycles in which GnRHa was administered at menstruation were analysed. Group B consisted of 72 cycles in which buserelin was used. Of these, 10 (13.9%) were with cysts (group B1) and 62 (86.1%) without cysts (group B2). Group T included 49 cycles in which triptorelin was injected. Of these, seven (14.2%) were with cysts (group T1) and 42 (85.7%) without cysts (group T2). Group L comprised 51 cycles in which leuprolide was administered. Of these, eight (15.7%) were with cysts (group L1) and 43 (84.3%) without cysts (group L2). All women with ovarian cysts had higher serum oestradiol concentrations and all except five underwent cyst aspiration with no complication. No differences were observed in the number of follicles and oocytes between groups B, T and L or between the groups with cysts and those without cysts. The pregnancy rate was similar in all groups. In conclusion, follicle cyst formation does not seem to be related to the use of a specific GnRHa, its short- or long-acting form or to the mode of administration. In addition, follicle cyst aspiration is a safe and successful solution to the problem of functionally active ovarian cysts.
authors.affiliation: 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Greece.
authors.forename: B C
authors.initials: BC
authors.lastname: Tarlatzis
authors.forename: H
authors.initials: H
authors.lastname: Bili
authors.forename: J
authors.initials: J
authors.lastname: Bontis
authors.forename: S
authors.initials: S
authors.lastname: Lagos
authors.forename: I
authors.initials: I
authors.lastname: Vatev
authors.forename: S
authors.initials: S
authors.lastname: Mantalenakis
mesh_terms: D000328:Adult; D002064:Buserelin / Q000009:adverse effects; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use; D010048:Ovarian Cysts / Q000139:chemically induced*; D011247:Pregnancy; D017329:Triptorelin Pamoate / Q000009:adverse effects
chemical_list: D006063:Chorionic Gonadotropin; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D016729:Leuprolide; D002064:Buserelin